Secure Communication Architecture and Protocol Controls Under ISO 27001 A.13

Establishing verifiable, secure data pathways between connected medical devices and external networks is the foundational requirement under both ISO 27001 Annex A.13 (Communications Security) and FDA premarket cybersecurity guidance. The challenge is technically non-trivial given the heterogeneity of communication protocols used across device classes — from ISO/IEEE 11073 in point-of-care devices to IoT-oriented standards such as oneM2M in broader healthcare networks.

A key mechanism for bridging the protocol gap is the use of a medical communication abstraction layer that dynamically assigns classification levels to air interfaces based on health regulatory requirements. As demonstrated in a 2017 patent from Qualcomm Incorporated, a medical communication abstraction layer executing on a computing node determines requirements associated with a classification level and establishes air interfaces meeting those requirements with peer nodes. This policy-driven data governance model aligns directly with ISO 27001 A.8 (information classification) and the FDA’s expectation for documented cybersecurity architecture in premarket submissions.

Protocol interoperability presents an equally significant security concern. Many connected medical devices operate on ISO/IEEE 11073, while broader healthcare networks rely on oneM2M. A 2017 patent from Keimyung University Industry-Academic Cooperation Foundation illustrates how a Common Services Entity (CSE) can determine whether an incoming message uses ISO/IEEE 11073 or oneM2M and convert accordingly — a capability that supports ISO 27001 A.13.1.1 (network controls) by preventing protocol-level ambiguity that could introduce vulnerabilities at the boundary layer. According to ISO, boundary-layer protocol translation logic must be treated as a security control point, not merely an interoperability convenience.

Connected device systems that include an intermediate communication device — such as a portable consumer electronic relay — also introduce chain-of-custody concerns for control data. A 2022 patent from F. Hoffmann-La Roche AG describes a control module within an intermediate device that receives and validates control data before forwarding it to the medical device’s critical operating functions. This design directly supports ISO 27001 A.14.2 (security in development and support processes) and the FDA’s requirement for defense-in-depth architectures in premarket submissions.

Device Provisioning, Registration, and Access Management Controls (ISO 27001 A.9)

ISO 27001 A.9 (Access Control) and A.12.5 (Control of Operational Software) require that only authorised devices access sensitive networks, and that operational configurations are verified before deployment. Automated and secure device provisioning addresses this requirement directly: a two-stage, segmented provisioning model isolates newly received devices on a temporary network before any access to production infrastructure is granted.

In the CareFusion 303, Inc. (2024) architecture, newly received medical devices connect to a predetermined temporary provisioning network — physically isolated from the healthcare organisation’s operational network — before any access to production management servers is granted. Access is only established when the device identifier is verified against a remote server’s authorisation list. This approach directly satisfies ISO 27001 A.9.1.2 (access to networks and network services) and aligns with FDA premarket expectations for demonstrating controlled network ingress for device populations.

“Access is only established when the device identifier is verified against a remote server’s authorisation list — a two-stage, segmented provisioning model that directly satisfies ISO 27001 A.9.1.2 and FDA premarket expectations for controlled network ingress.”

Automatic registration at the system level — particularly in laboratory and diagnostic environments — further supports asset inventory requirements. A 2024 patent from F. Hoffmann-La Roche AG describes a laboratory communication management unit that requests solution-specific configurations from remote infrastructure based on device-specific information transmitted over a defined first communication interface. This pattern ensures that device configuration is traceable, auditable, and driven by centralised policy — all core expectations of ISO 27001 A.12.1 (operational procedures and responsibilities). Critically, it also supports the FDA’s Software Bill of Materials (SBOM) expectations, since every device configuration event is logged and attributable.

Proxy-Based Cybersecurity Intermediaries and the Legacy Device Patch Management Dilemma

One of the most practically significant challenges in medical device cybersecurity is the prevalence of legacy or resource-constrained devices that cannot independently manage security update cycles. ISO 27001 A.12.6 (management of technical vulnerabilities) requires timely identification, evaluation, and remediation of known vulnerabilities — a standard that is difficult to meet for devices with locked firmware or long regulatory re-certification timelines. The FDA’s premarket guidance explicitly requires manufacturers to submit a plan for coordinated vulnerability disclosure and patching.

The patent literature offers a compelling architectural solution: the cybersecurity interface proxy box. As detailed in a 2022 patent from F. Hoffmann-La Roche AG, a proxy box is interposed between a fleet of medical devices and an update server. The proxy replicates the services present on connected medical devices, periodically polls the server for security updates, applies those updates to its own service instances, and allows the medical devices to consume the updated services — without requiring the devices themselves to be directly modified or re-certified. The patent text explicitly references FDA recommendations regarding cybersecurity vulnerability management, confirming the regulatory intent behind the design.

This proxy model also addresses ISO 27001 A.15 (supplier relationships), since it enables consistent security policy enforcement across third-party device integrations within a healthcare network. Additionally, it satisfies A.13.1.3 (segregation in networks) by maintaining a clear boundary between the update infrastructure and the device fleet. As ENISA has noted in its medical device security guidelines, proxy-based update architectures are increasingly recognised as a viable compliance pathway for resource-constrained device ecosystems.

Network-Level Security Risk Analysis and Anomaly Detection for ISO 27001 A.16

ISO 27001 A.16 (information security incident management) requires organisations to detect, classify, and respond to security events in a timely and systematic manner. The FDA’s premarket guidance similarly demands that manufacturers provide evidence of threat modelling and the capacity for real-time monitoring of cybersecurity-relevant events. Beyond device-level controls, network-level analytics are essential for identifying compromised or anomalous behaviour in connected medical device fleets.

A 2021 patent from China Academy of Telecommunications Technology presents a network data analysis function (NWDAF) entity that acquires UE operational information, analyses it to determine security risk type, and issues policy update instructions to network function entities or direct alerts to the affected terminal. While designed for mobile network contexts, the architecture maps directly onto medical device network monitoring requirements: the NWDAF’s risk-type classification and policy-triggered response model reflects ISO 27001 A.16.1.4 (assessment of and decision on information security events) and supports the FDA’s expectation for defined cybersecurity response procedures in premarket documentation.

Industrial control environments — which share many architectural features with hospital device networks — have similarly adopted layered computational fabrics to isolate security-critical workloads. A 2025 patent from Fisher-Rosemount Systems describes a transport network that securely provides communication between a computational fabric and physical devices, with containerised software modules performing control, monitoring, and configuration. This pattern is increasingly adopted in hospital device management platforms that must demonstrate ISO 27001-aligned network segmentation and secure software deployment practices. According to NIST‘s cybersecurity framework guidance, containerised workload isolation is a recognised technical control for operational technology environments.

Key Assignees and Innovation Trends in Medical Device Cybersecurity Patents

Analysis of the patent dataset reveals a concentration of cybersecurity-relevant medical device innovation among a small number of highly active assignees spanning jurisdictions including Japan, Spain, South Korea, the European Patent Office, and the United States. F. Hoffmann-La Roche AG is the most prolific assignee in the dataset, appearing in three patents across the Japanese and Spanish patent offices, with a portfolio covering the full lifecycle of connected device security.

Leading Assignees by Patent Coverage

• F. Hoffmann-La Roche AG — Three patents covering secure inter-device communication via intermediary control modules, automated device registration and configuration management, and proxy-based vulnerability management. The most comprehensive connected device security portfolio in the dataset.
• CareFusion 303, Inc. (a BD company) — Deep focus on secure network provisioning for hospital-deployed device fleets, with a segmented provisioning architecture representing a state-of-the-art approach to ISO 27001-aligned onboarding.
• Qualcomm Incorporated — Classification-driven air interface security, extending cybersecurity governance to the wireless transmission layer — a domain often underaddressed in traditional ISO 27001 implementations for medical devices.
• Fisher-Rosemount Systems — Industrial control system security patterns applicable to healthcare operational technology environments, including containerised application security and secure transport networks.
• China Academy of Telecommunications Technology — Network data analysis function (NWDAF) architecture for real-time risk detection and policy-triggered response, applicable to medical device fleet monitoring.
• Keimyung University Industry-Academic Cooperation Foundation — Protocol conversion security between ISO/IEEE 11073 and oneM2M, addressing boundary-layer vulnerabilities in heterogeneous healthcare networks.

Dominant Innovation Trends

Innovation trends across the dataset point toward four converging directions. First, increasing use of proxy and intermediary architectures to decouple security update cycles from device re-certification — resolving the fundamental tension between regulatory timelines and vulnerability management cadences. Second, automated, policy-driven device onboarding using segmented temporary networks that satisfy ISO 27001 A.9 without manual intervention. Third, classification-level-driven data governance across heterogeneous communication channels, extending ISO 27001 A.8 controls to the wireless transmission layer. Fourth, network-function-level analytics for real-time risk detection, providing the monitoring infrastructure required by both ISO 27001 A.16 and FDA premarket cybersecurity guidance.

“Protocol translation logic is a potential attack surface that must be governed under ISO 27001 A.13 and documented in FDA threat models — not merely treated as an interoperability convenience.”

The geographic spread of the dataset — spanning Japan, Spain, South Korea, the EPO, and the United States — also reflects the global regulatory convergence underway in medical device cybersecurity, as frameworks such as the IMDRF‘s principles for medical device cybersecurity align international expectations with FDA and ISO 27001 standards. Manufacturers seeking premarket clearance must increasingly demonstrate compliance with this converging multi-jurisdictional framework, making patent landscape analysis an essential input to regulatory strategy. PatSnap’s medical device intelligence platform provides the analytical infrastructure needed to map these trends across jurisdictions in real time.